The Pulmonary Fibrosis Foundation (PFF) is excited to announce that Timothy S. Blackwell, MD and Lisa Lancaster, MD both from Vanderbilt University, will serve as co-chairs for the PFF Summit 2017.


Timothy S. Blackwell, MD is the Ralph and Lulu Owen Professor of Medicine, Cancer Biology, and Cell and Molecular Biology at the Vanderbilt University School of Medicine. He has been the Director of the Division of Allergy, Pulmonary, and Critical Care Medicine and the Vanderbilt Center for Lung Research since 2007. Dr. Blackwell graduated from the University of Alabama School of Medicine in 1988, trained in Internal Medicine at Washington University in St. Louis, and completed a fellowship in Pulmonary and Critical Care at Vanderbilt University in 1995. He is a member of the American Thoracic Society, the American Society for Clinical Investigation, and the Association of American Physicians.  He has received a variety of honors for his research, including a scientific achievement award from the American Thoracic Society.  He was named the Parker B. Francis Lecturer at the American Thoracic Society annual conference in 2015.  Dr. Blackwell is an international leader in the study of interstitial lung diseases. His pioneering work has helped to define the role of the alveolar epithelium as a critical regulator of fibrotic remodeling in the lungs. His group established the importance of endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and he leads a program that has made important contributions in defining genetic susceptibility to familial and sporadic forms of IPF. In addition, Dr. Blackwell’s laboratory conducts highly innovative research related to molecular regulation of lung inflammation, airway remodeling, and tumorigenesis.


Lisa Lancaster, MD is an Associate Professor of Medicine and Director, Interstitial Lung Disease Program at Vanderbilt University. She is a nationally known expert in interstitial lung disease and IPF. She serves as Medical Director of the Interstitial Lung Disease Program and the IPF Clinical Trials Center at Vanderbilt University Medical Center and has served on steering committees of large national IPF clinical trials.  She has also served as the Lead Investigator on a large multinational IPF clinical trial. The Vanderbilt IPF Clinical Trials Center is part of the original 11-center NIH IPF Network and has been involved in 37 multi-center pharmaceutical company and NIH studies, including being a top enroller in most IPF clinical trials. In addition to serving as the site principal investigator for these multi-center trials, she also conducts research in sleep disorders in IPF, and is a member of steering committees for both the PFF Care Center Network and Patient Registry and the ILD